Our Research

The Hill Laboratory uses preclinical transplant and immunotherapy models, together with clinical sample analyses, to dissect the immunological mechanisms of transplant and cell therapy complications, aiming to improve patient outcomes through new therapies to prevent and treat immune toxicity, relapse and opportunistic infection. Research focuses on understanding the pathways of allogenic and CAR T cell reactivity resulting in graft-versus-host disease (GVHD), cytokine release syndrome (CRS) and anti-tumor immunity. The ultimate aim is to generate testable therapeutic interventions that attenuate GVHD and CRS whilst preventing tumor escape after cell therapy, without compromise of pathogen-specific immunity.